Profile data is unavailable for this security.
About the company
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
- Revenue in USD (TTM)0.00
- Net income in USD-47.90m
- Incorporated1998
- Employees29.00
- LocationCassava Sciences Inc6801 N CAPITAL OF TEXAS HIGHWAYBUILDING 1; SUITE 300AUSTIN 78731United StatesUSA
- Phone+1 (512) 501-2444
- Fax+1 (512) 614-0414
- Websitehttps://www.cassavasciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyra Biosciences Inc | 0.00 | -75.45m | 983.55m | 49.00 | -- | 2.52 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 998.52m | 150.00 | -- | 5.46 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Innoviva Inc | 311.59m | 181.39m | 1.01bn | 112.00 | 7.37 | 1.44 | 4.58 | 3.23 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Liquidia Corp | 15.97m | -107.69m | 1.02bn | 136.00 | -- | 11.81 | -- | 63.86 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.02bn | 267.00 | -- | -- | -- | 2.47 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 1.06bn | 29.00 | -- | 12.16 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.08bn | 296.00 | -- | 4.80 | -- | 10.17 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Silence Therapeutics plc | 33.55m | -44.39m | 1.09bn | 115.00 | -- | 6.20 | -- | 32.37 | -0.39 | -0.39 | 0.2848 | 1.13 | 0.1829 | -- | 5.37 | 291,718.30 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 1.10bn | 586.00 | -- | 0.9719 | -- | 30.73 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Pharvaris NV | 0.00 | -109.50m | 1.11bn | 82.00 | -- | 2.59 | -- | -- | -2.74 | -2.74 | 0.00 | 7.97 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
| Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.12bn | 197.00 | 16.59 | 5.03 | 4.66 | 1.97 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.13bn | 46.00 | -- | 3.53 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.73m | 6.32% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.24m | 5.19% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.09m | 2.53% |
| Geode Capital Management LLCas of 31 Mar 2024 | 901.84k | 2.09% |
| Gallacher Capital Management LLCas of 31 Mar 2024 | 585.38k | 1.35% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 372.00k | 0.86% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 316.39k | 0.73% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 216.50k | 0.50% |
| Clear Creek Financial Management LLCas of 31 Mar 2024 | 138.53k | 0.32% |
| Susquehanna Investment Group LLCas of 31 Mar 2024 | 105.43k | 0.24% |
